Clinical Trials Sector Scorecard, Q2 2022 Update – Thematic Research

Pages: 16 Published: December 27, 2021 Report Code: GDHCHT336

  • Overview
  • Key Players
  • Contents
  • FAQ
  • Listen
    Powered by iSpeech

In Q2 2022, there was increased activity in the virtual care space. Compared to Q1 2022, Novo Nordisk initiated more trials with virtual components and posted more jobs related to virtual care. Daiichi Sankyo and Takeda are planning a study in Japan that will look at the feasibility of using a wearable device to track lifestyle habits. Sanofi announced several social initiatives, including the successful pricing of its first bond linked to improving access to essential medicine, the launch of its Diversity, Equity & Inclusion (DE&I) board, and the launch of Foundation S – The Sanofi Collective, its philanthropic endowment fund.

The clinical trials sector scorecard report offers in-depth research into a specific theme (such as AI or cybersecurity). The report identifies winners and losers based on technology leadership, market position, and other factors. It also covers all themes within a sector, giving readers a strong sense of how everything fits together and how conflicting themes might interact with one another. Moreover, each sector scorecard identifies the companies that are most likely to succeed in a world filled with disruptive threats.

What are the key events that have impacted the clinical trials thematic scorecard in Q2 2022?

Some of the key events that have impacted the clinical trials thematic scorecard in Q2 2022 are as follows:

ESG

In May 2022, Merck KGaA announced that over the next five years, it was going to invest at sites in Germany, China, France, Switzerland, Ireland, and the US that will focus on targets for water consumption, waste management, and energy efficiency, to support meeting its goal to be climate-neutral by 2040.

Virtual care

 There were several interesting deals in the virtual care and digital health space in Q2 2022. Boehringer Ingelheim was sponsoring the UK’s first digital health training program for all NHS frontline staff. In May, Pfizer acquired ResApp Health, a digital health company developing smartphone apps for the diagnosis and management of the respiratory disease. Additionally, Roche partnered with Kaiku Health in May 2022 to offer cancer symptom management and support to clinics and patients via a digital platform.

AI

In Q2 2022, many strategic partnerships in AI were forged, but which had no overall impact on company scores. GSK and PathAI partnered in April this year to accelerate R&D programs in oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAI’s digital pathology technologies including its AIM-NASH tool. Standigm enter into an agreement with Merck Korea in May 2022 to accelerate its drug discovery research by adopting Merck’s AI software SYNTHIA. In June 2022, Owkin announced that it will use AI to design clinical trials for BMS, with an initial focus on cardiovascular disease.

For more insights on the key events impacting the clinical trial thematic scorecard, download a free report sample

Market Report Overview

Key events ESG, Virtual Care, and AI

Scope

  • GlobalData’s Clinical Trials Thematic Scorecard report provides a top-down, comprehensive outlook for key players in the clinical trial sector over the next two to four years.
  • These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.
  • The scorecard includes 53 companies from across the industry, including biopharmaceutical companies, biosimilar, and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
  • It is important to note that this scorecard is not an assessment of the current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.
  • The methodology section contains information on what data sources were used to generate the thematic scores for each company.
  • The scorecard is live on the PIC and will be updated quarterly.

Reasons to Buy

  • Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.
  • Understand which key themes should be addressed to drive the share price.
  • Understand which companies are best positioned for success within critical themes and why.
  • Learn which companies have underinvested in key themes and are most vulnerable to disruption.
  • Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
  • Help identify future winners and losers in drug development to inform partnership strategies.

Key Players

Takeda Pharmaceutical Co Ltd

Merck & Co Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Pfizer Inc

Johnson & Johnson

Boehringer Ingelheim

Parexel International Corp

F. Hoffmann-La Roche Ltd

Novartis AG

GSK Plc

Bayer AG

Eli Lilly and Co

IQVIA Holdings Inc

AbbVie Inc

Merck KGaA

Novo Nordisk AS

Catalent Inc

Gilead Sciences Inc

Thermo Fisher Scientific Inc

Astellas

Biogen Inc

Cipla Ltd

Lonza Group Ltd

Amgen Inc

Daiichi Sankyo Co Ltd

Vertex Pharmaceuticals Inc

WuXi AppTec Co Ltd

Charles River Laboratories International Inc

CSL Ltd

Reliance Life Sciences Pvt Ltd

Sanofi

Innovent Biologics Inc

Otsuka

Teva Pharmaceutical Industries Ltd

UCB

Dr. Reddy’s Laboratories Ltd

Regeneron Pharmaceuticals Inc

Samsung Bioepis Co Ltd

Sun Pharmaceutical Industries Ltd

Biocad

Cadila Pharmaceuticals Ltd

Celltrion Inc

Coherus BioSciences Inc

CSPC Pharmaceutical Group Ltd

Generium

Intas Pharmaceuticals Ltd

Lupin Ltd

Perrigo Co Plc

Seagen Inc

Shanghai Henlius Biotech Inc

Viatris Inc

Zydus Lifesciences

Table of Contents

Executive Summary

Introduction

• Pharma Theme Map

Clinical Trials Scorecard: Key Q2 2022 Updates

• Company Screen

• Thematic Screen

• Valuation Screen

Our Thematic Research Methodology

• How Our Pharma Scores Are Generated

Related Reports

About the Authors

About GlobalData

Frequently Asked Questions

The key events that have impacted the clinical trials thematic scorecard in Q2 2022 are ESG, virtual care, and AI.

Some of the key themes associated with the clinical trial market are empowered patient, geopolitics, cell and gene therapy, demographic changes, strategic alliances, big data, wearable tech, drug pricing and reimbursement, outsourcing, and cybersecurity.

Some of the key companies associated with the clinical trial market are Merck KGaA, Sanofi, Novo Nordisk, Daiichi Sankyo, Pfizer, Roche, Boehringer Ingelheim, GSK, and Bristol Myers Squib.

The key types of screens available in the clinical trial theme sector scorecard are thematic screen, valuation screen, and risk screen.

$1950

Can be used by individual purchaser only

$3900

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.